Abstract: Adenovirus for use in anti-tumour therapy which has specificity for tumour cells, especially for tumour cells that have reduced activity levels of the tumour suppressor p53. It is known that the majority of tumours characteristically exhibit reduced activity of the tumour repressor p53. In tumour-bearing patients, the adenovirus provides for an effective cross-presentation of tumour antigens, which can be neoantigens. e.g. having low immunogenicity, and hence supports the induction of tumour-specific immune cells, especially of tumour-specific CD8 T? cells. Further, the adenovirus in tumour patients stimulates the non-specific immune response by NK-cells, preferably both locally and systemically, and the adenovirus improves migration of immune cells. e.g. T-cells. NK-cells, and antigen-presenting cells (APC), e.g. dendritic cells, into the tumour, and the adenovirus improves the maturation of immune cells, especially of APC, and improves the cytolysis of tumour cells by immune cells.

Abstract: The invention provides manipulated adenovirus, i.e. a viral particle based on a manipulated adenovirus, for use as a medicament, especially for use in the treatment of tumours. The viral particle of the invention has the advantage of having a preference or specificity for tumour cells, yielding a preferred infection of tumour cells. The viral particle is based on adenovirus, especially type C, preferably serotype 2 (Ad2), more preferably serotype 5 (Ad5), in which the native entire fiber protein, and its coding sequence, respectively, is deleted and replaced by a fusion protein providing specificity for cell surface bound polysialic acid.

Abstract: The invention provides manipulated adenovirus, i.e. a viral particle based on a manipulated adenovirus, for use as a medicament, especially for use in the treatment of tumours. The viral particle of the invention has the advantage of having a preference or specificity for tumour cells, yielding a preferred infection of tumour cells. The viral particle is based on adenovirus, especially type C, preferably serotype 2 (Ad2), more preferably serotype 5 (Ad5), in which the native entire fiber protein, and its coding sequence, respectively, is deleted and replaced by a fusion protein providing specificity for cell surface bound polysialic acid.